Applied Therapeutics & Whole Animal Imaging

CCR/KI在利用小鼠研究癌症方面有着长期的记录。在过去十年中， 中心已经成功地培育出了许多小鼠模型，这些模型发展出的肿瘤与 与致病突变及其表型有关的人类疾病 特征包括进展到转移状态。现在KL和KL都有很强的驱动力 科学家和工程师使用这些模型来测试潜在的治疗策略，并探索 耐药机制。此外，这些型号是Kl工程师的重要资源，在 体内系统，用于测试肿瘤检测和监测设备、药物输送系统和 化疗反应。在目前的筹资期间，KL建立了一个新的机制，称为 应用治疗学和全动物成像(ATWAI)核心设施作为集中式存在 支持和鼓励这些翻译工作的资源。ATWAI核心在两个阶段开发 阶段。最终，核心建立了必要的基础设施，以支持对 对治疗剂的反应和抵抗力，特别是对整个动物成像方式的反应和抵抗力。这 仪器使中心成员能够评估体内的肿瘤动力学，包括跟踪 肿瘤的发展和转移及其对治疗的反应。接下来，在2008年，一个 聘请老鼠模型专家担任ATWAI核心代理经理，目标是最大限度地减少 在建立和进行临床前试验方面存在着无数的障碍。ATWAI管理器提供 为中心成员提供广泛和定制的咨询服务、调查人员培训和培训 执行实验，以实现现场高质量的生物传感器、诊断、 疫苗、化疗、基因治疗或药物输送和靶向治疗都是模式化的。因此，ATWAI CORE帮助中心成员将小鼠模型应用于潜在的疗法和刺激 KL工程师和科学家之间的合作，以实现药物输送和肿瘤监测的测试 系统处于适当的活体模型中。ATWAI核心的扩展计划用于新的科赫 研究所大楼，包括额外的工作人员和仪器。来自CCSG的支持对于 确保ATWAI核心的成功，这一目标与NCI推进的愿望完美契合 翻译研究。

The CCR/KI has a longstanding track record of using mice to study cancer. Over the last decade the Center has successfully generated numerous mouse models that develop tumors that closely resemble the human disease with regard to both the spectrum of contribufing mutations and their phenotypic characterisfics including progression to the metastafic state. There is now a strong drive by both Kl Scientists and Engineers to use these models to test potential therapeutic strategies and also explore mechanisms of drug resistance. Moreover, these models are a key resource for Kl Engineers, offering in vivo systems to test tumor detecfion and monitoring devices, drug delivery systems, and chemotherapeutic response. In the current funding period, the Kl has established a new facility, called the Applied Therapeutics & Whole Animal Imaging (ATWAI) Core Facility that exists as a centralized resource to support and encourage these translational efforts. The ATWAI Core developed in two phases. Inifially, the Core established the infrastructure necessary to support longitudinal studies of the response and resistance to therapeutic agents, particularly whole animal imaging modalities. This instrumentation has allowed Center members to assess tumor dynamics in vivo including tracking the development and metastasis of tumors and following their response to treatment. Next, in 2008, an expert in mouse models was recruited as Acting Manager of the ATWAI Core with the goal of minimizing the myriad hurdles that exist in setting up and conducting preclinical trials. The ATWAI manager provides Center members with a extensive and customized consultative services, investigator training, and handson execufion of experiments to enable on-site, high-quality in vivo trials for biosensors, diagnostics, vaccines, chemotherapies, gene therapy, or drug delivery and targefing modalifies. Thus, the ATWAI Core helps Center members to bring mouse models to bear on potenfial therapies, and spurs collaborafions between Kl engineers and scienfists to allow testing of drug delivery and tumor monitoring systems in appropriate in vivo models. An expansion of the ATWAI Core is planned for the new Koch Institute building, including addifional staff and instrumentation. Support from the CCSG is critical to ensure the success of this ATWAI Core, a goal that fits perfecfiy with the NCI's desire to advance translational research.